The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 4 | — | 5.6% | Below average | |
Quality | 6 | -462.5% | 7.6% | Below average | |
Safety | 26 | 1.5x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
IN8bio, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy IN8bio, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
INAB stock shows complete stability in its price target at $4 over the past 30 days, with an absence of any recent analyst revisions. This consistency reflects a state of anticipation awaiting clinical trial results, especially with only one analyst currently covering the price target, indicating low dispersion but limited depth in research coverage.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.